Study guide

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards)

PEBC Pharmacist Qualifying Examination Part I MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation

1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice

2 Chapter 2: Ethics, Scope of Practice & Safety Culture

2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement

3 Chapter 3: Pharmaceutical Calculations & Posology

3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)

4 Chapter 4: Compounding, Dispensing & Product Integrity

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control

5 Chapter 5: Clinical Pharmacology & Pharmacokinetics

5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities

6 Chapter 6: Evidence-Based Medicine & Literature Appraisal

6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics

7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD

7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)

8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation

8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)

9 Chapter 9: Endocrine & Metabolic Disorders

9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)

10 Chapter 10: Respiratory & Gastrointestinal Disorders

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis

11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship

11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

12 Chapter 12: Central Nervous System & Mental Health

12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome

13 Chapter 13: Special Populations, Pain Management & Substance Use

13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy

14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care

14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care

15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health

15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

16 Chapter 16: Immunization & Health Promotion

16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health

17 Chapter 17: Patient Care Process, Communication & Stewardship

17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards)

Key Takeaways Explain This Topic AI

Under the NAPRA Model Standards for Pharmacy Compounding of Non-Sterile Preparations, requirements are set by risk assessment into Level A (simple and moderate preparations in a separate compounding area), Level B (complex preparations or small quantities needing ventilation, such as hormones, in a dedicated room), and Level C (NIOSH Group 1 or very irritating hazards in a separate room at -2.5 Pa with at least 12 air changes per hour vented outside).

In the absence of published, stability-indicating analytical studies, standard beyond-use dates (BUD) apply: water-containing oral formulations have a maximum BUD of 14 days when refrigerated (2°C to 8°C); water-containing topical/dermal and mucosal liquids or semisolids have a maximum BUD of 30 days stored at controlled room temperature (20°C to 25°C); and non-aqueous formulations have a maximum BUD of 6 months (180 days) or the earliest expiry date of any active ingredient, whichever is shorter.

A Master Formulation Record (MFR) is the permanent master recipe and standard operating procedure created prior to compounding that specifies calculations, exact ingredient grades, container-closure systems, compounding steps, and quality control parameters, whereas a Compounding Record (CR) is the batch-specific log documenting actual manufacturer lot numbers, measured quantities, preparer and verifier signatures, and the unique internal batch number.

Volumetric and gravimetric compounding accuracy requires strict equipment protocols: electronic balances must operate within their Minimum Weighable Quantity (MWQ = Sensitivity Requirement / 0.05 for 5% maximum allowable error), and graduated cylinders must never be used to measure volumes below 20% of their rated capacity.

Pharmaceutical excipients dictate physical stability: suspending agents (e.g., methylcellulose, xanthan gum) increase vehicle viscosity to slow sedimentation per Stokes' Law; wetting agents (e.g., glycerin, propylene glycol) displace air from hydrophobic particles; and organic acid preservatives (e.g., sodium benzoate, sorbic acid) require an acidic vehicle (pH < 5.0) to remain in their active un-ionized antimicrobial state.

Last updated: October 2026

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards)

Pharmaceutical compounding represents a core professional competency for Canadian pharmacists. When commercial drug products are unavailable, unsuitable for a patient's clinical needs (e.g., pediatric dosing requirements, severe excipient allergies, dysphagia), or discontinued, pharmacy professionals formulate customized therapeutic preparations. In Canada, pharmacy compounding is regulated by provincial and territorial pharmacy regulatory authorities (PRAs) operating under national standards established by the National Association of Pharmacy Regulatory Authorities (NAPRA) , specifically the Model Standards for Pharmacy Compounding of Non-Sterile Preparations .

Regulatory Framework: Compounding vs. Manufacturing

A critical distinction on entry-to-practice examinations is the legal boundary separating pharmacy compounding from commercial pharmaceutical manufacturing under Health Canada's Policy on Manufacturing and Compounding Drug Products in Canada (POL-0051) :

Compounding: Occurs within a bona fide patient-pharmacist-prescriber relationship, triggered by a specific prescription or an anticipated historical prescription demand in limited quantities. Compounded preparations do not possess a Drug Identification Number (DIN) and cannot be distributed commercially for wholesale resale.

Manufacturing: Involves the large-scale mass production of standardized drug products for broad commercial distribution. Manufacturing falls exclusively under federal jurisdiction (Food and Drugs Act, Good Manufacturing Practices [GMP], and Health Canada Establishment Licensing). Patient-Specific Need / Prescription ---> Pharmacy Compounding (Provincial Regulatory Authority / NAPRA)

  • Mass Distribution / Resale Without Prescriptions ---> Commercial Manufacturing (Health Canada / GMP / DIN)
  • NAPRA Non-Sterile Compounding Risk Levels: A, B, and C

NAPRA's Model Standards for Pharmacy Compounding of Non-Sterile Preparations (2018) set three levels of requirements. The pharmacist chooses the level through a documented risk assessment that weighs the complexity of the preparation, the hazard classification of each ingredient (NIOSH list, WHMIS safety data sheet), the quantity, how often it is compounded, and the physical form (powders aerosolize; creams do not). NAPRA's decision tree routes occasional small quantities of lower-risk hazardous drugs to Level A or B, and Group 1 drugs to Level C:

Level Risk Profile & Typical Preparations Facility & Environmental Requirements Engineering Controls

Level A Simple and moderate preparations (USP <795> categories): for example solutions, suspensions, ointments and creams made from tablets or bulk powders, including preparations without published stability data. Also covers occasional small quantities of NIOSH Group 2 or 3 drugs that pose little risk to staff (NAPRA's examples: clonazepam, carbamazepine) Separate, designated compounding area away from dispensing traffic; smooth, cleanable surfaces; water supply and adequate lighting General compounding equipment; no special ventilation required

Level B Complex preparations (for example transdermal dosage forms, modified-release preparations, some suppositories for systemic effect), or small quantities of products that need ventilation : certain powders, aromatic products, allergenic products, and products with unintended effects such as hormones Dedicated room separate from the rest of the pharmacy, for larger workspace, storage and protection from cross-contamination A ventilated, closed room or a ventilated containment device for powders, hormones and allergens; PPE per risk assessment

Level C Hazardous compounding: NIOSH Group 1 drugs (antineoplastics such as methotrexate or mercaptopurine) and WHMIS health-hazard materials that are very irritating to the respiratory tract, skin or mucous membranes. Also applies to routine, large-quantity use of NIOSH Group 2 or 3 drugs when the risk assessment calls for it Separate room under negative pressure (−2.5 Pa) relative to surrounding areas; at least 12 air changes per hour (ACPH) with all air exhausted to the exterior; hazardous-drug storage and signage Containment primary engineering control (C-PEC: containment ventilated enclosure or Class I/II biological safety cabinet) vented outside; hazardous-drug PPE (chemotherapy gloves, gown, respiratory protection per risk assessment)

Important

A community pharmacy cannot crush antineoplastic tablets or weigh hormone powders on an open dispensary counter. Antineoplastics (NIOSH Group 1) need Level C containment. Hormone and other irritating powders need at least Level B ventilation, or Level C when used routinely in large quantities. NIOSH's 2024 update replaced the three groups with two tables. NAPRA's standards still use the Group 1/2/3 wording from the 2016 list, so apply the risk assessment rather than memorizing one drug-to-level pairing.

Beyond-Use Dating (BUD) Standards

The Beyond-Use Date (BUD) is the date or time after which a compounded preparation must not be used, administered, or stored. Unlike a manufacturer's expiration date —which is determined through extensive real-time and accelerated stability testing in final commercial packaging—a BUD is assigned conservatively by the compounding professional based on chemical stability, physical degradation risks, and microbial vulnerability.

Default Maximum BUDs (NAPRA / USP <795> Framework)

In the absence of published, stability-indicating analytical studies or official pharmacopoeial monographs, compounders must strictly observe the following conservative default BUD parameters: NON-STERILE COMPOUNDED PREPARATION

  • │
  • ┌─────────────────────────────────┴─────────────────────────────────┐
  • ▼ ▼
  • AQUEOUS FORMULATION NON-AQUEOUS FORMULATION
  • │ │
  • ┌─────────┴─────────┐ ▼
  • ▼ ▼ MAXIMUM 6 MONTHS
  • ORAL LIQUID TOPICAL / MUCOSAL (180 Days) or earliest
  • MAX 14 DAYS MAX 30 DAYS API expiry date
  • (Refrigerated: (Controlled Room Temp: (Room Temp: 20°C–25°C)
  • 2°C–8°C) 20°C–25°C)

Water-Containing Oral Formulations:

Maximum BUD: 14 days

Storage Requirement: Controlled refrigerated storage ( 2 ∘ C 2^\circ\text{C} 2 ∘ C to 8 ∘ C 8^\circ\text{C} 8 ∘ C )

Rationale: Water acts as a catalyst for chemical hydrolysis and provides a fertile medium for bacterial and fungal proliferation. Refrigeration significantly slows hydrolytic reaction kinetics and microbial growth.

Examples: Compounded pediatric oral suspensions (e.g., omeprazole oral suspension in sodium bicarbonate, baclofen oral suspension).

Water-Containing Topical, Dermal, and Mucosal Liquids and Semisolids:

Maximum BUD: 30 days

Storage Requirement: Controlled room temperature ( 20 ∘ C 20^\circ\text{C} 2 0 ∘ C to 25 ∘ C 25^\circ\text{C} 2 5 ∘ C )

Rationale: Topical applications carry lower risks of systemic microbial infection compared to ingested liquids, but microbial bioburden and phase separation remain significant risks over time.

Examples: Compounded hydrophilic creams, lotions, topical gels, and mucosal ointments.

Non-Aqueous Formulations:

Maximum BUD: 6 months (180 days) or the earliest expiration date of any raw active pharmaceutical ingredient (API), whichever is shorter.

Storage Requirement: Controlled room temperature ( 20 ∘ C 20^\circ\text{C} 2 0 ∘ C to 25 ∘ C 25^\circ\text{C} 2 5 ∘ C )

Rationale: In the absence of water (water activity a w < 0.60 a_w < 0.60 a w ​ < 0.60 ), microbial growth is inhibited, and hydrolytic degradation cannot occur. Chemical oxidation and physical stability dictate longevity.

Examples: Anhydrous ointments (white petrolatum base), polyethylene glycol (PEG) troches, gelatin capsules containing dry powder mixtures, and oleaginous suppositories (cocoa butter).

Note

A compounder may assign an extended BUD beyond default parameters only if the exact formulation (including identical API salt, concentration, excipient vehicles, and container-closure system) is supported by published, peer-reviewed, stability-indicating analytical assay literature (e.g., Canadian Journal of Hospital Pharmacy , Trissel's Stability of Compounded Formulations ). The BUD must never exceed the expiration date of any individual component.

Master Formulation Records vs. Compounding Records

NAPRA standards mandate two distinct, auditable documentation systems to guarantee consistency, traceability, and quality assurance in compounding operations:

Document Core Purpose Timing of Creation Key Mandatory Contents

Master Formulation Record (MFR) The permanent "master recipe" and standard operating procedure for a specific preparation Created and verified before the preparation is compounded for the first time Official or assigned name, strength, and dosage form; Complete list of all ingredients with exact quantities and pharmacopoeial grades (e.g., USP/NF); Container-closure system specifications; Step-by-step preparation method with mixing times and temperatures; Quality control parameters (expected appearance, pH range, weight variation); Assigned BUD and rationale/citation; Special handling and safety precautions

Compounding Record (CR) The batch-specific execution log documenting the actual compounding event Completed during and immediately after compounding each individual batch Name, strength, and dosage form matching the MFR; Master Formulation Record reference number; Unique internal batch/lot number and prescription number; Actual manufacturer, lot number, and expiration date of each ingredient used; Exact measured weights and volumes of all ingredients; Actual results of quality control checks (e.g., measured pH, capsule weights); Signatures/initials of preparer and verifying pharmacist/technician; Actual BUD assigned and total quantity/yield prepared

Equipment Calibration, Maintenance & Volumetric Accuracy

Compounding precision depends directly on the proper maintenance, calibration, and operational boundaries of pharmacy equipment:

1. Prescription Balances and the Minimum Weighable Quantity (MWQ)

Electronic prescription balances must be verified daily using National Institute of Standards and Technology (NIST) Class 1 or Class 2 standard weights. To prevent unacceptably high percentage errors when weighing small quantities, compounders apply the Minimum Weighable Quantity (MWQ) formula:

MWQ = Sensitivity Requirement (SR) Maximum Acceptable Error Percentage (0.05) = SR × 20 \text{MWQ} = \frac{\text{Sensitivity Requirement (SR)}}{\text{Maximum Acceptable Error Percentage (0.05)}} = \text{SR} \times 20 MWQ = Maximum Acceptable Error Percentage (0.05) Sensitivity Requirement (SR) ​ = SR × 20

For a traditional Class A torsion balance or electronic balance with a sensitivity requirement of 6 mg 6\text{ mg} 6 mg and an acceptable error of 5 % 5\% 5% ( 0.05 0.05 0.05 ):

MWQ = 6 mg 0.05 = 120 mg \text{MWQ} = \frac{6\text{ mg}}{0.05} = 120\text{ mg} MWQ = 0.05 6 mg ​ = 120 mg

If a prescription requires less than 120 mg 120\text{ mg} 120 mg of active drug powder on such a balance, the compounder cannot weigh it directly; an aliquot dilution (solid-in-solid or solid-in-liquid) must be performed using an inert diluent (e.g., lactose) to ensure the weighed mass meets or exceeds the MWQ.

2. Volumetric Glassware and the 20% Capacity Rule

Volumetric measurements must be conducted using certified pharmaceutical glassware:

Cylindrical Graduates: Possess uniform internal diameter and provide high volumetric accuracy throughout the column. Always preferred over conical graduates for precise measurements.

Conical Graduates: Have flared sides; measurement accuracy decreases rapidly as volume increases. Used primarily for facilitating mixing or dissolution, not precision measurement.

The 20% Volumetric Rule: A liquid volume must never be measured in a graduate cylinder if the volume is less than 20% of the cylinder's rated capacity (e.g., do not measure less than 20 mL 20\text{ mL} 20 mL in a 100 mL 100\text{ mL} 100 mL cylinder, or less than 10 mL 10\text{ mL} 10 mL in a 50 mL 50\text{ mL} 50 mL cylinder). Measuring below 20% introduces unacceptable meniscus parallax and surface tension errors.

Small Volumes (< 5 mL): Must be measured using calibrated oral syringes, analytical pipettes, or micropipettes rather than graduated cylinders. Meniscus Reading: Read at the EXACT BOTTOM of the concave liquid curve at eye level.

Rule of Thumb: Select the smallest graduate cylinder that will hold the desired volume (> 20% capacity).

Pharmaceutical Excipients: Roles and Physical Pharmacy

Excipients are inactive substances intentionally added to active drug substances to facilitate manufacturing, enhance physical stability, prevent microbial proliferation, improve palatability, or optimize bioavailability:

1. Suspending Agents and Stokes' Law

In pharmaceutical suspensions (coarse dispersions of insoluble solid particles in liquid media), particles tend to settle over time. Sedimentation rate is governed by Stokes' Law :

v = 2 r 2 ( ρ p − ρ f ) g 9 η v = \frac{2 r^2 (\rho_p - \rho_f) g}{9 \eta} v = 9 η 2 r 2 ( ρ p ​ − ρ f ​ ) g ​

Where v v v is sedimentation velocity, r r r is particle radius, ρ p \rho_p ρ p ​ is particle density, ρ f \rho_f ρ f ​ is fluid density, g g g is gravitational acceleration, and η \eta η is dynamic viscosity of the medium.

Mechanism: Suspending agents (e.g., methylcellulose, carboxymethylcellulose sodium, xanthan gum, acacia, carbomers, commercial vehicles like Ora-Plus ) are hydrophilic polymers that increase vehicle viscosity ( η \eta η ). By increasing η \eta η and reducing particle size ( r r r ) via trituration, sedimentation velocity ( v v v ) is minimized, preventing rapid caking and ensuring uniform dosing upon shaking.

2. Wetting and Levigating Agents

Hydrophobic drug powders (e.g., sulfur, hydrocortisone) trap air pockets on their surfaces, causing them to float on liquid vehicles rather than dispersing. Wetting agents lower the interfacial tension and contact angle between the solid particles and liquid vehicle, displacing entrapped air.

Levigation: The process of reducing particle size and dispersing powders into a smooth paste using a small amount of liquid (levigating agent) in which the solid is insoluble.

Polarity Matching Rule:

For water-soluble / water-washable bases (e.g., vanishing cream, hydrophilic petrolatum, polyethylene glycol): use glycerin, propylene glycol, or purified water .

For oleaginous / greasy bases (e.g., white petrolatum, mineral oil bases): use mineral oil .

3. Antimicrobial Preservatives

Preservatives prevent microbial growth in multi-dose water-containing preparations. Common agents include sodium benzoate, benzoic acid, potassium sorbate, methylparaben, propylparaben, and benzyl alcohol .

Note

The pH Dependence of Acidic Preservatives: Benzoic acid and sorbic acid exert antimicrobial action only in their un-ionized (lipid-soluble) state , which allows them to penetrate bacterial cell membranes. Because their pKa values fall between 4.2 4.2 4.2 and 4.8 4.8 4.8 , they require an acidic pH (< 5.0) to remain active. In neutral or alkaline vehicles (pH > 6.0), they dissociate into inactive ions, leaving the formulation unprotected against microbial contamination.

4. Antioxidants

Antioxidants inhibit oxidative chemical degradation by terminating free-radical chain reactions or acting as sacrificial reducing agents:

Aqueous Systems: Ascorbic acid (Vitamin C), sodium bisulfite, sodium metabisulfite.

Oil Systems: Alpha-tocopherol (Vitamin E), butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA).

5. Emulsifiers and the Hydrophile-Lipophile Balance (HLB) System

Emulsifiers stabilize immiscible oil-and-water blends by forming interfacial films around dispersed droplets. The HLB scale ranges from 1 to 20:

Low HLB (3 to 6): Lipophilic agents that stabilize water-in-oil (w/o) emulsions (e.g., sorbitan monooleate [Span 80]).

High HLB (8 to 16): Hydrophilic agents that stabilize oil-in-water (o/w) emulsions (e.g., polysorbate 80 [Tween 80]).

Clinical & Dispensing Case Scenario: Compounding an Oral Suspension

A community pharmacy receives a prescription for pediatric spironolactone 5 mg/mL oral suspension, 100 mL, for a 6-month-old infant with congestive heart failure. Commercial liquid spironolactone is not marketed in Canada.

Step-by-Step Procedure:

Level of Compounding: Spironolactone appears on the NIOSH 2016 hazardous drug list as a Group 2 non-antineoplastic drug. Because manipulating commercial tablets into powder creates hazardous dust, the risk assessment places this occasional preparation at Level B : a dedicated room and a ventilated containment device (CVE). It would move to Level C if the pharmacy compounded large quantities routinely.

Master Formulation Verification: Retrieve the validated MFR. Spironolactone 5 mg/mL compounded from commercial 25 mg tablets in a 1:1 mixture of Ora-Plus and Ora-Sweet is supported by published stability data (Allen & Erickson, Am J Health-Syst Pharm ).

Trituration & Levigation: Count 20 spironolactone 25 mg tablets ( 500 mg 500\text{ mg} 500 mg total). Pulverize to a fine, uniform powder in a glass mortar. Add a few drops of glycerin (wetting agent) to form a smooth, uniform paste.

Vehicle Incorporation: Geometrically incorporate 50 mL of Ora-Plus (suspending vehicle) into the paste. Transfer quantitatively to a calibrated cylindrical graduate, rinsing the mortar with portions of Ora-Sweet. Bring to a final volume of 100 mL with Ora-Sweet.

Quality Control & Packaging: Measure pH (target 4.0 − 5.0 4.0 - 5.0 4.0 − 5.0 ), inspect color and uniformity, package in an amber, child-resistant oral bottle with an oral syringe adapter. Affix auxiliary labels: "Shake Well Before Use" and "Hazardous Drug - Handle with Care" .

BUD Assignment: Supported by peer-reviewed published stability data, assign a BUD of 60 days stored at controlled room temperature (or 14 days refrigerated if relying on default USP/NAPRA guidelines without stability citations).